Nov 20, 2017· Comment from Association for Accessible Medicines· FDA-2017-N-3615-0097
The Association for Accessible Medicines (AAM) is pleased to provide comments to the Food and Drug Administration (FDA or the Agency) in response to the Agency's Federal Register Notice entitled "Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access; Public Meeting; Request for Comments."